Generalized Pustular Psoriasis Clinical Trial
Official title:
Effisayil™ ON: An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Spesolimab Treatment in Patients With Generalized Pustular Psoriasis (GPP)
This study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous study with spesolimab (1368-0013 or 1368-0027). The goal of this study is to find out how well people with GPP tolerate long-term treatment with spesolimab. The study also tests whether spesolimab helps improve GPP symptoms and how quickly the symptoms improve after a flare-up. Every participant gets spesolimab for almost 5 years (252 weeks). Depending on their symptoms and whether they had a GPP flare during the previous trial, they get spesolimab every few weeks. When participants have a GPP flare during this trial, they get spesolimab as an infusion into a vein. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. To assess the study endpoints, doctors regularly check participants' skin.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06100991 -
CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
|
||
| Recruiting |
NCT06013969 -
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
|
Phase 4 | |
| Completed |
NCT05512598 -
HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
|
Phase 1 | |
| Recruiting |
NCT05670821 -
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
|
||
| Recruiting |
NCT06323356 -
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
|
Phase 3 | |
| Completed |
NCT05239039 -
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
|
Phase 3 | |
| Completed |
NCT04399837 -
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
|
Phase 2 | |
| Not yet recruiting |
NCT06433531 -
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
|
Phase 1 | |
| Completed |
NCT03942042 -
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
|
Phase 4 | |
| Completed |
NCT06391996 -
Biologic Therapy for Generalized Pustular Psoriasis
|
||
| Completed |
NCT03782792 -
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
|
Phase 2 | |
| Completed |
NCT03619902 -
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
|
Phase 2 | |
| Active, not recruiting |
NCT04566471 -
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
|
||
| Recruiting |
NCT06295692 -
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
|
Phase 3 | |
| Completed |
NCT05200247 -
An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
|
Phase 3 | |
| Active, not recruiting |
NCT05366855 -
Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis
|
Phase 3 | |
| Completed |
NCT05352893 -
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
|
Phase 3 |